Search Results - "HILLEGASS, W. B"

Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype‐Guided Antiplatelet Therapy by Harada, S, Zhou, Y, Duncan, S, Armstead, AR, Coshatt, GM, Dillon, C, Brott, BC, Willig, J, Alsip, JA, Hillegass, WB, Limdi, NA

“…Precision medicine entails tailoring treatment based on patients' unique characteristics. As drug therapy constitutes the cornerstone of treatment for most…”
Get full text

Relation between activated clotting time during angioplasty and abrupt closure by NARINS, C. R, HILLEGASS, W. B, NELSON, C. L, TCHENG, J. E, HARRINGTON, R. A, PHILLIPS, H. R, STACK, R. S, CALIFF, R. M

“…The purpose of this study was to determine whether the degree of heparin anticoagulation during coronary angioplasty, as measured by the activated clotting…”
Get full text

Clinical determinants and impact of hemorrhagic lesions on intestinal pathology in preterm infants with surgical necrotizing enterocolitis by Garg, P M, Denton, M X, Talluri, R, Ostrander, M M, Middleton, C, Sonani, H, Varshney, N, Hillegass, W B

“…We sought to determine the clinical and histopathological factors associated with intestinal hemorrhage and its correlation with clinical outcomes in neonates…”
Get more information

Clinical determinants of intestinal failure and death in preterm infants with surgical necrotizing enterocolitis by Garg, P M, Denton, M X, Talluri, R, Ansari, M A Y, Riddick, R, Ostrander, M M, McDonald, A G, Premkumar, M H, Hillegass, W B, Garg, P P

“…We sought to investigate the clinical determinants of intestinal failure and death in preterm infants with surgical NEC. Retrospective comparison of clinical…”
Get more information

Safe use of platelet GP IIb/IIIa inhibitors by FERGUSON, J. J, KEREIAKES, D. J, ADGEY, A. A. J, FOX, K. A. A, HILLEGASS, W. B, PFISTERER, M, VASSANELLI, C

“…The platelet membrane glycoprotein IIb/IIIa receptor inhibitor abciximab is used for the treatment of patients undergoing high-risk percutaneous coronary…”
Get full text

Economic issues in glycoprotein IIb/IIIa receptor therapy by Hillegass, William B., Newman, Anne R., Raco, Dominic L.

“…Efficacy, safety, and cost will determine the use of glycoprotein IIb/IIIa therapy in patients with acute coronary syndromes or those patients undergoing…”
Get full text

Abciximab therapy in percutaneous intervention : Economic issues in the United States by GOKLANEY, A. K, MURPHY, J. D, HILLEGASS, W. B

“…Whether abciximab therapy should be the standard of care during percutaneous intervention in the United States depends on its efficacy, safety, and economics…”
Get full text

Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications by Hillegass, W B, Newman, A R, Raco, D L

“…In addition to efficacy and safety, cost is an important determinant of the use of glycoprotein IIb/IIIa (GPIIb/IIIa) therapy in patients with acute coronary…”
Get full text

Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience by Hillegass, William B, Dean, Neal A, Liao, Laurence, Rhinehart, Rodney G, Myers, Paul R

“…OBJECTIVES The objective of this study was to test the hypothesis that the intracoronary administration of a direct donor of nitric oxide is a safe and…”
Get full text

Safe use of platelet GP IIb/IIIa inhibitors by Ferguson, James J., Kereiakes, Dean J., Adgey, A.A.Jennifer, Fox, Keith A.A., Hillegass, William B., Pfisterer, Matthias, Vassanelli, Corrado

“…The platelet membrane glycoprotein IIb/IIIa receptor inhibitor abciximab is used for the treatment of patients undergoing high-risk percutaneous coronary…”
Get full text

Abciximab therapy in percutaneous intervention: Economic issues in the United States by Goklaney, Anil K., Murphy, Joshua D., Hillegass, William B.

“…Whether abciximab therapy should be the standard of care during percutaneous intervention in the United States depends on its efficacy, safety, and economics…”
Get full text

Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction by Hillegass, William B., Jollis, James G., Granger, Christopher B., Ohman, E.Magnus, Califf, Robert M., Mark, Daniel B.

“…Thrombolytic therapy for acute myocardial infarction (AMI) has reduced mortality at the expense of additional intracranial hemorrhages. To determine whether…”
Get full text

Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience by Singh, Mandeep, Reeder, Guy S, Ohman, E.Magnus, Mathew, Verghese, Hillegass, William B, Anderson, R.David, Gallup, Dianne S, Garratt, Kirk N, Holmes, David R

“…OBJECTIVES This study aimed to determine whether pre-existing angiographic thrombus was associated with adverse in-hospital and six-month outcomes after…”
Get full text

A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty by Hillegass, William B., Ohman, E.Magnus, Leimberger, Jeffrey D., Califf, Robert M.

“…The usefulness of calcium antagonists to reduce restenosis after coronary angioplasty remains uncertain despite 5 randomized trials involving 919 patients…”
Get full text

Stent procedure complicated by thrombus formation distal to the lesion within a muscle bridge by Agirbasli, Mehmet, Hillegass Jr, William B., Chapman, Gregory D., Brott, Brigitta C.

“…We report here a case of a patient who underwent percutaneous intervention to the left anterior descending artery, complicated by thrombus formation within the…”
Get full text

Clinical correlates of cerebellar injury in preterm infants with surgical necrotizing enterocolitis by Garg, P M, Pittman, I, Yi, J, Shetty, A, Taylor, C, Reddy, K, Inder, T E, Varshney, N, Hillegass, W B, Garg, P P

“…The preterm infants are at risk of cerebellar injury and the risk factors for necrotizing enterocolitis (NEC) associated cerebellar injury are not fully…”
Get more information

Use of calcium channel antagonists in myocardial revascularization procedures by Califf, Robert M., Tardiff, Barbara E., Pieper, Karen S., Hillegass, William B.

“…Calcium channel antagonists possess a number of properties that may be beneficial after revascularization procedures. Therefore, we present an overview of the…”
Get full text

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial by Lederman, Robert J, Mendelsohn, Farrell O, Anderson, R David, Saucedo, Jorge F, Tenaglia, Alan N, Hermiller, James B, Hillegass, William B, Rocha-Singh, Krishna, Moon, Thomas E, Whitehouse, MJ, Annex, Brian H

“…Recombinant fibroblast growth factor-2 (rFGF-2) improves perfusion in models of myocardial and hindlimb ischaemia. We investigated whether one or two doses of…”
Get full text

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: Observations from the ESPRIT Trial by TOLLESON, Thaddeus R, O'SHEA, J. Conor, BITTL, John A, HILLEGASS, William B, WILLIAMS, Kathryn A, LEVINE, Glenn, HARRINGTON, Robert A, TCHENG, James E

“…We evaluated the relationship between the degree of heparin anticoagulation and clinical efficacy and bleeding in patients undergoing contemporary percutaneous…”
Get full text

Economic issues in glycoprotein IIb/IIIa receptor therapy: IIb/IIIa today: changing the practice of cardiovascular medicine by HILLEGASS, W. B, NEWMAN, A. R, RACO, D. L

Get full text